Benjamine Liu – Co-Founder and CEO of TrialSpark
Benjamine Liu is a computational biologist and neuroscientist working at Oxford’s Translational Neuroscience and Dementia Research Group. He focuses on using big data, sequencing technology and machine learning techniques to advance diagnosis and treatment of neurological disorders.
While undertaking his graduate work, he observed the many bottlenecks in clinical trials impeded their efforts to develop new treatments for patients. This insight led him to found TrialSpark as a technology company dedicated to reinventing clinical trials.
Benjamine Liu is co-founder and CEO of TrialSpark, a technology company revolutionizing drug development. His research involves using machine learning, AI and healthcare big data (transcriptomics, proteomics, metabolomics imaging) to advance diagnostics and therapeutics for neurodegenerative diseases like Alzheimer’s and Parkinson’s.
His work sits at the intersection of chemistry and biology, with research focused on understanding the chemical mechanisms of enzymes which catalyze rare, but important steps in natural product synthesis biosynthesis. To date he has published over 40 papers in respected journals.
He is also a frequent presenter at both national and international conferences.
Benjamine Liu is the Chief Executive and Co-Founder of TrialSpark, a technology company that is revolutionizing drug development by empowering doctors to set up FDA compliant trial sites within existing practices, opening trials to the 99% of patients not currently participating in clinical studies. A Rhodes Scholar at Oxford, his DPhil thesis utilized machine learning, AI, healthcare big data such as genomics, proteomics, transcriptomics, metabolomics imaging to develop diagnostics and therapies for Parkinson’s and Alzheimer’s diseases.
Liu uses recycled materials such as old books, clothing and household items to portray how organisms grow and repair themselves; her work embodies this holistic approach to life while fulfilling her longing for deep connection and belonging. She currently resides in New York City.
Benjamine Liu has amassed an estimated net worth of $20 Million. As CEO and Co-Founder of TrialSpark, an innovative technology company reinventing drug development, his net worth stands at approximately $20 Million. A Rhodes Scholar from Oxford, he studied under Sir Simon Lovestone where his research focused on machine learning techniques combined with big healthcare data like genomics, proteomics, metabolomics imaging transcriptomics to develop diagnostics and therapies for Parkinson’s and Alzheimer’s diseases using genomic sequencing, proteomics proteomics metabolomics imaging transcriptomics etc to develop diagnostics/therapeutics/therapy; TrialSpark partners with doctors to set up FDA compliant trial sites within existing practices so more patients participate and gain access to research treatments!